Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com -- Kura Oncology Inc (NASDAQ:KURA) stock jumped 5% in premarket trading Friday after the clinical-stage biopharmaceutical company announced it received a $30 million milestone payment from Kyowa Kirin.
The payment comes under the companies’ collaboration agreement and follows the dosing of the first patient in the KOMET-017 Phase 3 registrational trials of ziftomenib, Kura’s investigational oral menin inhibitor for cancer treatment.
The KOMET-017 trials, launched on September 29, 2025, consist of two independent, global, randomized double-blind, placebo-controlled Phase 3 studies. These trials will evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML).
According to Kura, KOMET-017 represents the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. The once-daily oral drug is being developed as a precision medicine for cancer treatment.
The milestone payment highlights progress in Kura’s clinical development program as it advances ziftomenib through late-stage trials, which appears to be driving investor optimism in Friday’s premarket trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.